Literature DB >> 34339458

Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.

Nicholas Van Sciver1,2, Makoto Ohashi1, Nicholas P Pauly1, Jillian A Bristol1, Scott E Nelson1, Eric C Johannsen1,3, Shannon C Kenney1,3.   

Abstract

The Epstein-Barr virus (EBV) human herpesvirus is associated with B-cell and epithelial-cell malignancies, and both the latent and lytic forms of viral infection contribute to the development of EBV-associated tumors. Here we show that the Hippo signaling effectors, YAP and TAZ, promote lytic EBV reactivation in epithelial cells. The transcriptional co-activators YAP/TAZ (which are inhibited by Hippo signaling) interact with DNA-binding proteins, particularly TEADs, to induce transcription. We demonstrate that depletion of either YAP or TAZ inhibits the ability of phorbol ester (TPA) treatment, cellular differentiation or the EBV BRLF1 immediate-early (IE) protein to induce lytic EBV reactivation in oral keratinocytes, and show that over-expression of constitutively active forms of YAP and TAZ reactivate lytic EBV infection in conjunction with TEAD family members. Mechanistically, we find that YAP and TAZ interact with, and activate, the EBV BZLF1 immediate-early promoter. Furthermore, we demonstrate that YAP, TAZ, and TEAD family members are expressed at much higher levels in epithelial cell lines in comparison to B-cell lines, and find that EBV infection of oral keratinocytes increases the level of activated (dephosphorylated) YAP and TAZ. Finally, we have discovered that lysophosphatidic acid (LPA), a known YAP/TAZ activator that plays an important role in inflammation, induces EBV lytic reactivation in epithelial cells through a YAP/TAZ dependent mechanism. Together these results establish that YAP/TAZ are powerful inducers of the lytic form of EBV infection and suggest that the ability of EBV to enter latency in B cells at least partially reflects the extremely low levels of YAP/TAZ and TEADs in this cell type.

Entities:  

Year:  2021        PMID: 34339458     DOI: 10.1371/journal.ppat.1009783

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  4 in total

Review 1.  Epstein-Barr virus: Biology and clinical disease.

Authors:  Blossom Damania; Shannon C Kenney; Nancy Raab-Traub
Journal:  Cell       Date:  2022-09-15       Impact factor: 66.850

Review 2.  Epigenetic control of the Epstein-Barr lifecycle.

Authors:  Rui Guo; Benjamin E Gewurz
Journal:  Curr Opin Virol       Date:  2021-12-08       Impact factor: 7.121

3.  ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells.

Authors:  Nicholas Van Sciver; Makoto Ohashi; Dhananjay M Nawandar; Nicholas P Pauly; Denis Lee; Kathleen R Makielski; Jillian A Bristol; Sai Wah Tsao; Paul F Lambert; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2021-11-08       Impact factor: 6.823

4.  Type 1 and Type 2 Epstein-Barr viruses induce proliferation, and inhibit differentiation, in infected telomerase-immortalized normal oral keratinocytes.

Authors:  Deo R Singh; Scott E Nelson; Abigail S Pawelski; Juan A Cantres-Velez; Alisha S Kansra; Nicholas P Pauly; Jillian A Bristol; Mitchell Hayes; Makoto Ohashi; Alejandro Casco; Denis Lee; Stuart A Fogarty; Paul F Lambert; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2022-10-03       Impact factor: 7.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.